T-DM1 myths: 'it is chemotherapy' and hair loss fears

T-DM1, whose full name is trastuzumab emtansine and brand name Kadcyla, is often described as chemotherapy, and that causes a lot of worry. The truth sits in between. T-DM1 is an antibody-drug conjugate: the HER2-targeted antibody trastuzumab is joined to a chemotherapy payload called DM1. The antibody carries the payload to cancer cells with a lot of HER2 on their surface, where it is released inside the cell. So it does contain chemotherapy, but it is delivered in a far more targeted way than standard chemotherapy. That is why its side effects look different. Complete hair loss is uncommon with T-DM1. Some people notice mild thinning, but most keep their hair, which is very different from the chemotherapy many people had before surgery. Sickness is usually mild, and very low white cell counts are much less common than with standard chemotherapy. T-DM1 does have its own side effects to watch for, including tiredness, low platelets, raised liver enzymes, tingling in the hands and feet, nosebleeds and, less often, effects on the heart or lungs. It is given as a drip once every three weeks, and many people carry on working and living fairly normally during treatment. Understanding what T-DM1 really is can help you prepare realistically, neither fearing the worst nor overlooking symptoms that need attention.

Partly chemotherapy, delivered differently

The payload is chemotherapy, but the antibody takes it mainly to HER2-positive cells.

Most people keep their hair

Complete hair loss is uncommon; mild thinning happens in some people.

Its own side effects still matter

Low platelets, liver changes and tingling are the ones your team watches most closely.

Correcting myths should not swing too far the other way. T-DM1 is easier for many people, but it is not side-effect free.

Tiredness is common

Many people feel tired, sometimes for several days after each dose, and it can build over the course of treatment.

Some people stop early

In the main trial, a noticeable minority stopped T-DM1 because of side effects, often low platelets, liver changes or tingling, and usually switched to trastuzumab.

Tingling can linger

Nerve changes usually improve after treatment, but can take months and occasionally persist.

What this page cannot tell you

It cannot predict which side effects you will get or how strongly. Your team monitors you at every visit and adjusts treatment if needed.

Because T-DM1 feels milder than expected, some people ignore symptoms that matter. Contact your team promptly about the following.

Bleeding or bruising

Nosebleeds that do not stop, bleeding gums, black stools or unexplained bruises can mean low platelets.

Signs of liver strain

Yellowing of the skin or eyes, dark urine or pain under the right ribs need checking quickly.

Reactions during or after the drip

Flushing, chills, fever, itching or feeling faint during an infusion, or in the hours after it, should be reported to the nurses straight away. These reactions are uncommon and usually settle with treatment, but the first infusion is run more slowly and followed by a longer period of observation for this reason.

Breathlessness, cough or swollen ankles

These can rarely point to effects on the lungs or heart and should be assessed promptly.